glp 1 dangers How Dangerous Is Gastroparesis? The promise and peril of

Trial data have shown decreases in serious cardiovascular complications, including cardiovascular mortality, nonlethal heart attacks, and nonfatal cerebrovascular accidents, among individuals with type 2 diabetes and pre-existing cardiovascular pathology or high cardiovascular risk [3,5,13,14,37]

either owns or uses the EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY trademarks under license

ED Relevant Adverse Effects As use continues to expand, the same physiologic effects that drive the benefits of GLP-1 receptor agonists also underlie their adverse effects and ED presentations

Questions to ask Can we start at a lower dose and adjust it slowly based on my response? What markers will we track to know if the dose is working? Whats the plan if I need to increase? How does this interact with my other medications? (Especially important if youre on HRT for menopause.) What to expect Many telehealth providers now offer low-dose GLP-1 programs

While preclinical studies support this hypothesis, robust clinical evidence remains limited

The primary endpoint is a three-point major adverse cardiovascular event endpoint that includes death from cardiovascular causes, non-fatal myocardial infarction (MI), or nonfatal stroke over a study period of 54 months